

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problems Mailbox.**

**THIS PAGE BLANK (USPTO)**

**THIS PAGE BLANK (USPTO)**

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
6 December 2001 (06.12.2001)

PCT

(10) International Publication Number  
**WO 01/92221 A1**

(51) International Patent Classification<sup>7</sup>: **C07C 401/00, A61K 31/59**

(21) International Application Number: **PCT/US01/17662**

(22) International Filing Date: **31 May 2001 (31.05.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:  
**60/208,199 31 May 2000 (31.05.2000) US**

(71) Applicant: **WISCONSIN ALUMNI RESEARCH FOUNDATION [US/US]; 614 North Walnut Street, Madison, WI 53705 (US).**

(72) Inventors: **DELUCA, Hector, F.; 1809 Highway BB, Deerfield, WI 53531 (US). SICINSKI, Rafal, R.; ul. Waszyngtona 33 m. 150, PL-04-030 Warsaw (PL).**

(74) Agents: **WOZNY, Thomas, M. et al.; Andrus, Scales, Starke & Sawall, LLP, Suite 1100, 100 East Wisconsin Avenue, Milwaukee, WI 53202 (US).**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **2-ETHYL AND 2-ETHYLIDENE-19-NOR-VITAMIN D COMPOUNDS**

(57) Abstract: Biologically active 19-nor vitamin D analogs substituted at C-2 in the A-ring with an ethylidene or an ethyl group. These compounds have preferential activity on mobilizing calcium from bone and either high or normal intestinal calcium transport activity which allows their in vivo administration for the treatment of metabolic bone diseases where bone loss is a major concern. These compounds are also characterized by high cell differentiation activity.



**WO 01/92221 A1**

## 2-ETHYL AND 2-ETHYLIDENE-19-NOR-VITAMIN D COMPOUNDS

## BACKGROUND OF THE INVENTION

This invention relates to vitamin D compounds, and more particularly to vitamin  
5 D derivatives substituted at the carbon 2 position.

The natural hormone,  $1\alpha,25$ -dihydroxyvitamin  $D_3$  and its analog in ergosterol series, i.e.  $1\alpha,25$ -dihydroxyvitamin  $D_2$  are known to be highly potent regulators of calcium homeostasis in animals and humans, and more recently their activity in cellular differentiation has been established, Ostrem et al., Proc. Natl. Acad. Sci. USA, 84, 2610  
10 (1987). Many structural analogs of these metabolites have been prepared and tested, including  $1\alpha$ -hydroxyvitamin  $D_3$ ,  $1\alpha$ -hydroxyvitamin  $D_2$ , various side chain homologated vitamins and fluorinated analogs. Some of these compounds exhibit an interesting separation of activities in cell differentiation and calcium regulation. This difference in activity may be useful in the treatment of a variety of diseases.

15 Recently, a new class of vitamin D analogs has been discovered, i.e. the so called 19-nor-vitamin D compounds, which are characterized by the replacement of the A-ring exocyclic methylene group (carbon 19), typical of the vitamin D system, by two hydrogen atoms. Biological testing of such 19-nor-analogs (e.g.,  $1\alpha,25$ -dihydroxy-19-nor-vitamin  $D_3$ ) revealed a selective activity profile with high potency in inducing cellular  
20 differentiation, and very low calcium mobilizing activity. Thus, these compounds are potentially useful as therapeutic agents for the treatment of malignancies, or the treatment of various skin disorders. Two different methods of synthesis of such 19-nor-vitamin D analogs have been described (Perlman et al., Tetrahedron Lett. 31, 1823 (1990); Perlman et al., Tetrahedron Lett. 32, 7663 (1991), and DeLuca et al., U.S. Pat. No. 5,086,191).

25 In U.S. Pat. No. 4,666,634,  $2\beta$ -hydroxy and alkoxy (e.g., ED-71) analogs of  $1\alpha,25$ -dihydroxyvitamin  $D_3$  have been described and examined by Chugai group as potential drugs for osteoporosis and as antitumor agents. See also Okano et al., Biochem. Biophys. Res. Commun. 163, 1444 (1989). Other 2-substituted (with hydroxyalkyl, e.g., ED-120, and fluoroalkyl groups) A-ring analogs of  $1\alpha,25$ -dihydroxyvitamin  $D_3$  have also  
30 been prepared and tested (Miyamoto et al., Chem. Pharm. Bull. 41, 1111 (1993); Nishii et al., Osteoporosis Int. Suppl. 1, 190 (1993); Posner et al., J. Org. Chem. 59, 7855 (1994), and J. Org. Chem. 60, 4617 (1995)).


Recently, 2-substituted analogs of  $1\alpha,25$ -dihydroxy-19-norvitamin  $D_3$  have also been synthesized, i.e. compounds substituted at 2-position with hydroxy or alkoxy groups (DeLuca et al., U.S. Pat. No. 5,536,713), which exhibit interesting and selective activity profiles. All these studies indicate that binding sites in vitamin D receptors can  
5 accommodate different substituents at C-2 in the synthesized vitamin D analogs.

### SUMMARY OF THE INVENTION

The discovery of the hormonally active form of vitamin  $D_3$ ,  $1\alpha, 25$ -dihydroxyvitamin  $D_3$  ( $1\alpha,25$ -(OH) $_2D_3$ , calcitriol, 1; Figure 1), has greatly stimulated  
10 research into its physiology and chemistry. As previously noted, it has been established that 1 not only regulates the mineral metabolism in animals and humans, but also exerts potent effects upon cell proliferation and cellular differentiation. Therefore, the chemistry of vitamin D has been recently focused on the design and synthesis of analogs that can exert selective biological actions.


15 In a previous investigation of the structure-activity relationship of the vitamin D molecule, an analog of the natural hormone 1,  $1\alpha,25$ -dihydroxy-2-methylene-19-norvitamin  $D_3$  (2), was prepared in which the exocyclic methylene group is transposed, in comparison with 1, from C-10 to C-2. Also,  $2\alpha$ -methyl analog 3 was obtained by selective hydrogenation of 2. Both analogs were characterized by significant biological  
20 potency, enhanced especially in their isomers in the 20S-series.

In a continuing search for biologically active vitamin D compounds novel 19-nor analogs of 1, substituted at C-2 with ethylidene (4a,b and 5a,b) and ethyl (6a,b and 7a,b) groups, have now been synthesized and tested. Structurally the novel 2-ethylidene analogs belong to a class of 19-nor vitamin D compounds characterized by the general formula I  
25 shown below:




where  $Y_1$  and  $Y_2$ , which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group, and where the group R represents  
 5 any of the typical side chains known for vitamin D type compounds.

Structurally the novel 2-ethyl analogs belong to a class of 19-nor vitamin D compounds characterized by the general formula II shown below:




where  $Y_1$  and  $Y_2$ , which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group, and where the group R represents any of the typical side chains known for vitamin D type compounds.

More specifically R can represent a saturated or unsaturated hydrocarbon radical of 1 to 35 carbons, that may be straight-chain, branched or cyclic and that may contain one or more additional substituents, such as hydroxy- or protected-hydroxy groups, fluoro, carbonyl, ester, epoxy, amino or other heteroatomic groups. Preferred side chains of this type are represented by the structure below:



where the stereochemical center (corresponding to C-20 in steroid numbering) may have the R or S configuration, (i.e. either the natural configuration about carbon 20 or the 20-epi configuration), and where Z is selected from Y, -OY, -CH<sub>2</sub>OY, -C≡CY, -CH=CHY, and -CH<sub>2</sub>CH<sub>2</sub>CH=CR<sup>3</sup>R<sup>4</sup>, where the double bond may have the cis or trans geometry, and where Y is selected from hydrogen, methyl, -COR<sup>5</sup> and a radical of the structure:








where m and n, independently, represent the integers from 0 to 5, where R<sup>1</sup> is selected from hydrogen, deuterium, hydroxy, protected hydroxy, fluoro, trifluoromethyl, and C<sub>1-5</sub>-alkyl, which may be straight chain or branched and, optionally, bear a hydroxy or protected-hydroxy substituent, and where each of R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup>, independently, is selected from deuterium, deuteroalkyl, hydrogen, fluoro, trifluoromethyl and C<sub>1-5</sub> alkyl, which may be straight-chain or branched, and optionally, bear a hydroxy or protected-hydroxy substituent, and where R<sup>1</sup> and R<sup>2</sup>, taken together, represent an oxo group, or an alkylidene group, =CR<sup>2</sup>R<sup>3</sup>, or the group -(CH<sub>2</sub>)<sub>p</sub>-, where p is an integer from 2 to 5, and where R<sup>3</sup> and R<sup>4</sup>, taken together, represent an oxo group, or the group -(CH<sub>2</sub>)<sub>q</sub>-, where q is an integer from 2 to 5, and where R<sup>5</sup> represents hydrogen, hydroxy, protected hydroxy,

C<sub>1-5</sub> alkyl or -OR<sup>7</sup> where R<sup>7</sup> represents C<sub>1-5</sub> alkyl, and wherein any of the CH-groups at positions 20, 22, or 23 in the side chain may be replaced by a nitrogen atom, or where any of the groups -CH(CH<sub>3</sub>)-, -CH(R<sup>3</sup>)-, or -CH(R<sup>2</sup>)- at positions 20, 22, and 23, respectively, may be replaced by an oxygen or sulfur atom.


5        The wavy lines, e.g. to the substituents at C-2 and at C-20 indicate that those substituents may have either the R or S configuration.

10        Specific important examples of side chains with natural 20*R*-configuration are the structures represented by formulas (a), (b), (c), (d) and (e) below. i.e. the side chain as it occurs in 25-hydroxyvitamin D<sub>3</sub> (a); vitamin D<sub>3</sub> (b); 25-hydroxyvitamin D<sub>2</sub> (c); vitamin D<sub>2</sub> (d); and the C-24 epimer of 25-hydroxyvitamin D<sub>2</sub> (e):





Specific important examples of side chains with the unnatural 20S (also referred to as the 20-epi) configuration are the structures presented by formulas (f), (g), (h), (i) and (j) below:



5

The above novel compounds exhibit a desired, and highly advantageous, pattern of biological activity. The synthesized vitamins were tested for their ability to bind the porcine intestinal vitamin D receptor. The presented results (Figure 5) indicate that 2-

ethylidene-19-norvitamins, possessing methyl group from ethylidene moiety directed toward C-3, i.e., trans in relation to C(6)-C(7) bond (isomers E), are more active than  $1\alpha,25-(\text{OH})_2\text{D}_3$  in binding to VDR, whereas their counterparts with *cis* relationship between ethylidene methyl substituent and C(7)-H group (isomers Z) exhibit significantly reduced affinity for the receptor. The competitive binding analysis showed also that  $2\alpha$ -ethyl-19-norvitamins bind to the receptor better than their isomers with  $2\beta$ -ethyl substituents (Figure 6). In the next assay, the cellular activity of the synthesized compounds was established by studying their ability to induce differentiation of human promyelocyte HL-60 cells into monocytes. *E* isomer of (20*S*)-2-ethylidene-19-norvitamin  $\text{D}_3$  (Figure 7) and both  $2\alpha$ -ethyl-19-norvitamins (Figure 8) are more potent than  $1\alpha,25-(\text{OH})_2\text{D}_3$  in this assay, whereas the remaining tested compounds are almost equivalent to the hormone 1. Both *E* isomers of 2-ethylidene-19-norvitamins, when tested *in vivo* in rats (Table 1) exhibited very high calcemic activity, the (20*S*)-compound being especially potent. On the contrary, isomeric *Z* compounds are significantly less active. 2-Ethyl-19-norvitamins have some ability to mobilize calcium from bone but not to the extent of the hormone 1, while being inactive in intestine. The only exception is the  $2\alpha$ -ethyl isomer from the 20*S*-series which shows strong calcium mobilization response and marked intestinal activity.

These compounds are thus highly specific in their calcemic activity. Their preferential activity on mobilizing calcium from bone and either high or normal intestinal calcium transport activity allows the *in vivo* administration of these compounds for the treatment of metabolic bone diseases where bone loss is a major concern. Because of their preferential calcemic activity on bone, these compounds would be preferred therapeutic agents for the treatment of diseases where bone formation is desired, such as osteoporosis, especially low bone turnover osteoporosis, steroid induced osteoporosis, senile osteoporosis or postmenopausal osteoporosis, as well as osteomalacia and renal osteodystrophy. The treatment may be transdermal, oral or parenteral. The compounds may be present in a composition in an amount from about  $0.1\mu\text{g/gm}$  to about  $50\mu\text{g/gm}$  of the composition, and may be administered in dosages of from about  $0.01\mu\text{g/day}$  to about  $50\mu\text{g/day}$ .

The compounds of the invention are also especially suited for treatment and prophylaxis of human disorders which are characterized by an imbalance in the immune system, e.g. in autoimmune diseases, including multiple sclerosis, diabetes mellitus, host versus graft reaction, lupus, atherosclerosis, and rejection of transplants; and additionally  
5 for the treatment of inflammatory diseases, such as inflammatory bowel disease, rheumatoid arthritis and asthma, as well as the improvement of bone fracture healing and improved bone grafts. Acne, alopecia especially chemically induced alopecia (e.g. resulting from chemotherapy), skin conditions such as dermatitis, eczema, keratosis, dry skin (lack of dermal hydration), undue skin slackness (insufficient skin firmness), insufficient sebum  
10 secretion and wrinkles, as well as hypocalcemia, hypoparathyroidism and hypertension are other conditions which may be treated with the compounds of the invention.

The above compounds are also characterized by high cell differentiation activity. Thus, these compounds also provide therapeutic agents for the treatment of psoriasis, or as an anti-cancer agent, especially against leukemia, colon cancer, breast cancer and prostate  
15 cancer. The compounds may be present in a composition to treat psoriasis, cancer, and/or the above list of diseases in an amount from about 0.01  $\mu\text{g/gm}$  to about 100  $\mu\text{g/gm}$  of the composition, and may be administered topically, transdermally, orally or parenterally in dosages of from about 0.01  $\mu\text{g/day}$  to about 100  $\mu\text{g/day}$ .

This invention also provides novel intermediate compounds formed during the  
20 synthesis of the end products.

This invention also provides a novel synthesis for the production of the end products of structures I and II. Two different synthetic paths were devised, both based on Lythgoe type Wittig-Horner coupling of the A-ring fragments, the corresponding phosphine oxides prepared from quinic acid, with the protected 25-hydroxy Grundmann's  
25 ketone. In the first method, the allylic phosphine oxides were substituted at C-4' with the ethylidene group whereas in the alternative approach the introduction of ethylidene moiety was performed in the final step of the synthesis, by Wittig reaction of the intermediate 2-oxo-vitamin D analog. The selective catalytic hydrogenation of 2-ethylidene analogs of 1 $\alpha$ ,25-dihydroxy-19-norvitamin D<sub>3</sub> provided the corresponding 2 $\alpha$ - and 2 $\beta$ -ethyl  
30 compounds.

## BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 illustrates the general structural formulae for  $1\alpha,25$ -dihydroxyvitamin  $D_3$ ,  $1\alpha,25$ -dihydroxy-2-methylene-19-norvitamin  $D_3$ , and  $1\alpha,25$ -dihydroxy-2 $\alpha$ -methyl-19-norvitamin  $D_3$ , and further illustrates the general structural formulae for the four 2-ethylidene-19-nor-vitamins and the four 2-ethyl-19-nor-vitamins of the present invention synthesized and tested herein;

Figure 2 illustrates the configurations and preferred conformations of the 4'-ethylidene intermediates 16 and 17 used in the synthesis disclosed herein;

Figure 3a illustrates the  $\alpha$ - and  $\beta$ - forms of the A-ring chair conformers for vitamin D compounds in solutions;

Figure 3b illustrates that the presence of bulky 2-alkyl substituents, characterized by large conformational free energy A values, shifts the A-ring conformational equilibrium of the synthesized 2-ethyl-19-nor-vitamins toward the conformers with the equatorial C(2)-substituents;

Figure 3c illustrates that a strong interaction (designated as  $A^{(1,3)}$ -strain) exists between the methyl group from the ethylidene moiety and equatorial hydroxyls at C-1 or C-3, and results in a strong bias toward conformers with an axial orientation of this hydroxy group to which the methyl from ethylidene fragment is directed; and

Figure 4 illustrates the conformational equilibrium in ring A of 2-methylene-19-norvitamin 2 (a) and the preferred, energy minimized (PC MODEL 6.0, *Serena Software*) A-ring conformations of the synthesized analogs: 4a,b (b), 5a,b (c), 6a,b (d) and 7a,b (e).

Figure 5a is a graph illustrating the relative activity of a 2-ethylidene-19-nor-vitamins (isomers *E* and *Z*) and  $1\alpha,25$ -dihydroxyvitamin  $D_3$  to compete for binding of [ $^3H$ ]-1,25-(OH) $_2$ - $D_3$  to the pig intestinal nuclear vitamin D receptor;

Figure 5b is a graph similar to Fig. 5a except illustrating the relative activity of individual compounds 2 $\alpha$  and 2 $\beta$ -ethyl-19-nor-vitamins and  $1\alpha,25$ -dihydroxyvitamin  $D_3$  to compete for binding of [ $^3H$ ]-1,25-(OH) $_2$ - $D_3$  to the vitamin D pig intestinal nuclear receptor;

Figure 6a is a graph illustrating the percent HL-60 cell differentiation as a function of the concentration of the 2-ethylidene-19-nor-vitamins as compared to 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>; and

Figure 6b is a graph illustrating the percent HL-60 cell differentiation as a function of the concentration of the 2 $\alpha$  and 2 $\beta$ -ethyl-19-nor-vitamins as compared to 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

### DETAILED DESCRIPTION OF THE INVENTION

As used in the description and in the claims, the term "hydroxy-protecting group" signifies any group commonly used for the temporary protection of hydroxy functions, such as for example, alkoxycarbonyl, acyl, alkylsilyl or alkylarylsilyl groups (hereinafter referred to simply as "silyl" groups), and alkoxyalkyl groups. Alkoxycarbonyl protecting groups are alkyl-O-CO- groupings such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, benzyloxycarbonyl or allyloxycarbonyl. The term "acyl" signifies an alkanoyl group of 1 to 6 carbons, in all of its isomeric forms, or a carboxyalkanoyl group of 1 to 6 carbons, such as an oxalyl, malonyl, succinyl, glutaryl group, or an aromatic acyl group such as benzoyl, or a halo, nitro or alkyl substituted benzoyl group. The word "alkyl" as used in the description or the claims, denotes a straight-chain or branched alkyl radical of 1 to 10 carbons, in all its isomeric forms. Alkoxyalkyl protecting groups are groupings such as methoxymethyl, ethoxymethyl, methoxyethoxymethyl, or tetrahydrofuranyl and tetrahydropyranyl. Preferred silyl-protecting groups are trimethylsilyl, triethylsilyl, t-butyl dimethylsilyl, dibutylmethylsilyl, diphenylmethylsilyl, phenyldimethylsilyl, diphenyl-t-butylsilyl and analogous alkylated silyl radicals. The term "aryl" specifies a phenyl-, or an alkyl-, nitro- or halo-substituted phenyl group.

A "protected hydroxy" group is a hydroxy group derivatised or protected by any of the above groups commonly used for the temporary or permanent protection of hydroxy functions, e.g. the silyl, alkoxyalkyl, acyl or alkoxycarbonyl groups, as previously defined. The terms "hydroxyalkyl", "deuteroalkyl" and "fluoroalkyl" refer to an alkyl radical substituted by one or more hydroxy, deuterium or fluoro groups respectively.

It should be noted in this description that the term "24-homo" refers to the addition of one methylene group and the term "24-dihomo" refers to the addition of two methylene groups at the carbon 24 position in the side chain. Likewise, the term "trihomo" refers to the addition of three methylene groups. Also, the term "26,27-dimethyl" refers to the addition of a methyl group at the carbon 26 and 27 positions so that for example  $R^3$  and  $R^4$  are ethyl groups. Likewise, the term "26,27-diethyl" refers to the addition of an ethyl group at the 26 and 27 positions so that  $R^3$  and  $R^4$  are propyl groups.

In the following lists of compounds, the particular isometric form of the ethylidene substituent attached at the carbon 2 position should be added to the nomenclature. For example, if the methyl group of the ethylidene substituent is in its (E) configuration, then the term "2(E)" should be included in each of the named compounds. If the methyl group of the ethylidene substituent is in its (Z) configuration, then the term "2(Z)" should be included in each of the named compounds. In addition, if the methyl group attached at the carbon 20 position is in its epi or unnatural configuration, the term "20(S)" or "20-epi" should be included in each of the following named compounds. Also, if the side chain contains an oxygen atom substituted at any of positions 20, 22 or 23, the term "20-oxa", "22-oxa" or "23-oxa", respectively, should be added to the named compound. The named compounds could also be of the vitamin  $D_2$  or  $D_4$  type if desired.

Specific and preferred examples of the 2-ethylidene-compounds of structure I when the side chain is unsaturated are:

2-ethylidene-19-nor-1,25-dihydroxy-22,23-dehydrovitamin  $D_3$ ;

2-ethylidene-19-nor-24-homo-1,25-dihydroxy-22,23-dehydrovitamin  $D_3$ ;

2-ethylidene-19-nor-24-dihomo-1,25-dihydroxy-22,23-dehydrovitamin  $D_3$ ;

2-ethylidene-19-nor-24-trihomo-1,25-dihydroxy-22,23-dehydrovitamin  $D_3$ ;

2-ethylidene-19-nor-26,27-dimethyl-24-homo-1,25-dihydroxy-22,23-dehydrovitamin  $D_3$ ;

2-ethylidene-19-nor-26,27-dimethyl-24-dihomo-1,25-dihydroxy-22,23-dehydrovitamin  $D_3$ ;

2-ethylidene-19-nor-26,27-dimethyl-24-trihomo-1,25-dihydroxy-22,23-dehydrovitamin  $D_3$ ;

2-ethylidene-19-nor-26,27-diethyl-24-homo-1,25-dihydroxy-22,23-dehydrovitamin D<sub>3</sub>;

2-ethylidene-19-nor-26,27-diethyl-24-dihomo-1,25-dihydroxy-22,23-dehydrovitamin D<sub>3</sub>;

5 2-ethylidene-19-nor-26,27-diethyl-24-trihomo-1,25-dihydroxy-22,23-dehydrovitamin D<sub>3</sub>;

2-ethylidene-19-nor-26,27-dipropoyl-24-homo-1,25-dihydroxy-22,23-dehydrovitamin D<sub>3</sub>;

10 2-ethylidene-19-nor-26,27-dipropyl-24-dihomo-1,25-dihydroxy-22,23-dehydrovitamin D<sub>3</sub>; and

2-ethylidene-19-nor-26,27-dipropyl-24-trihomo-1,25-dihydroxy-22,23-dehydrovitamin D<sub>3</sub>.

With respect to the above unsaturated compounds, it should be noted that the double bond located between the 22 and 23 carbon atoms in the side chain may be in either the (E) or (Z) configuration. Accordingly, depending upon the configuration, the term "22,23(E)" or "22,23(Z)" should be included in each of the above named compounds. Also, it is common to designate the double bond located between the 22 and 23 carbon atoms with the designation " $\Delta^{22}$ ". Thus, for example, the first named compound above could also be written as 2-ethylidene-19-nor-22,23(E)- $\Delta^{22}$ -1,25-(OH)<sub>2</sub>D<sub>3</sub> where the double bond is in the (E) configuration. Similarly, if the methyl group attached at carbon 20 is in the unnatural configuration, this compound could be written as 2-ethylidene-19-nor-20(S)-22,23(E)- $\Delta^{22}$ -1,25-(OH)<sub>2</sub>D<sub>3</sub>.

Specific and preferred examples of the 2-ethylidene-compounds of structure I when the side chain is saturated are:

25 2-ethylidene-19-nor-1,25-dihydroxyvitamin D<sub>3</sub>;

2-ethylidene-19-nor-24-homo-1,25-dihydroxyvitamin D<sub>3</sub>;

2-ethylidene-19-nor-24-dihomo-1,25-dihydroxyvitamin D<sub>3</sub>;

2-ethylidene-19-nor-24-trihomo-1,25-dihydroxyvitamin D<sub>3</sub>;

2-ethylidene-19-nor-26,27-dimethyl-24-homo-1,25-dihydroxyvitamin D<sub>3</sub>;

30 2-ethylidene-19-nor-26,27-dimethyl-24-dihomo-1,25-dihydroxyvitamin D<sub>3</sub>;

2-ethylidene-19-nor-26,27-dimethyl-24-trihomo-1,25-dihydroxyvitamin D<sub>3</sub>;  
 2-ethylidene-19-nor-26,27-diethyl-24-homo-1,25-dihydroxyvitamin D<sub>3</sub>;  
 2-ethylidene-19-nor-26,27-diethyl-24-dihomo-1,25-dihydroxyvitamin D<sub>3</sub>;  
 2-ethylidene-19-nor-26,27-diethyl-24-trihomo-1,25-dihydroxyvitamin D<sub>3</sub>;  
 2-ethylidene-19-nor-26,27-dipropyl-24-homo-1,25-dihydroxyvitamin D<sub>3</sub>;  
 2-ethylidene-19-nor-26,27-dipropyl-24-dihomo-1,25-dihydroxyvitamin D<sub>3</sub>; and  
 2-ethylidene-19-nor-26,27-dipropyl-24-trihomo-1,25-dihydroxyvitamin D<sub>3</sub>.

As noted previously, the above saturated side chain compounds should have the appropriate 2(E) or 2(Z) configuration and/or carbon 20 configuration added to the nomenclature. For example, particularly preferred compounds are:

19-nor-2(E)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>;  
 19-nor-2(Z)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>;  
 19-nor-2(E)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>; and  
 19-nor-2(Z)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

In the following lists of compounds, the particular isometric form of the ethyl substituent attached at the carbon 2 position should be added to the nomenclature. For example, if the ethyl group is in the alpha configuration, the term "2 $\alpha$ -methyl" should be included in each of the named compounds. If the ethyl group is in the beta configuration, the term "2 $\beta$ -ethyl" should be included in each of the named compounds. In addition, if the methyl group attached at the carbon 20 position is in its epi or unnatural configuration, the term "20(S)" or "20-epi" should be included in each of the following named compounds. Also, if the side chain contains an oxygen atom substituted at any of positions 20, 22 or 23, the term "20-oxa," "22-oxa" or "23-oxa," respectively, should be added to the named compound. The named compounds could also be of the vitamin D<sub>2</sub> or D<sub>4</sub> type if desired.

Specific and preferred examples of the 2-ethyl-compounds of structure II when the side chain is unsaturated are:

2-ethyl-19-nor-1,25-dihydroxy-22,23-dehydrovitamin D<sub>3</sub>;  
 2-ethyl-19-nor-24-homo-1,25-dihydroxy-22,23-dehydrovitamin D<sub>3</sub>;  
 2-ethyl-19-nor-24-dihomo-1,25-dihydroxy-22,23-dehydrovitamin D<sub>3</sub>;



2-ethyl-19-nor-24-trihomo-1,25-dihydroxy-22,23-dehydrovitamin D<sub>3</sub>;

2-ethyl-19-nor-26,27-dimethyl-24-homo-1,25-dihydroxy-22,23-dehydrovitamin

D<sub>3</sub>;

2-ethyl-19-nor-26,27-dimethyl-24-dihomo-1,25-dihydroxy-22,23-

5 dehydrovitamin D<sub>3</sub>;

2-ethyl-19-nor-26,27-dimethyl-24-trihomo-1,25-dihydroxy-22,23-

dehydrovitamin D<sub>3</sub>;

2-ethyl-19-nor-26,27-diethyl-24-homo-1,25-dihydroxy-22,23-dehydrovitamin

D<sub>3</sub>;

10 2-ethyl-19-nor-26,27-diethyl-24-dihomo-1,25-dihydroxy-22,23-dehydrovitamin

D<sub>3</sub>;

2-ethyl-19-nor-26,27-diethyl-24-trihomo-1,25-dihydroxy-22,23-dehydrovitamin

D<sub>3</sub>;

2-ethyl-19-nor-26,27-dipropyl-24-homo-1,25-dihydroxy-22,23-dehydrovitamin

15 D<sub>3</sub>;

2-ethyl-19-nor-26,27-dipropyl-24-dihomo-1,25-dihydroxy-22,23-dehydrovitamin

D<sub>3</sub>; and

2-ethyl-19-nor-26,27-dipropyl-24-trihomo-1,25-dihydroxy-22,23-

dehydrovitamin D<sub>3</sub>.

20 With respect to the above unsaturated compounds, it should be noted that the double bond located between the 22 and 23 carbon atoms in the side chain may be in either the (E) or (Z) configuration. Accordingly, depending upon the configuration, the term "22,23(E)" or "22,23(Z)" should be included in each of the above named compounds. Also, it is common to designate the double bond located between the 22 and 23 carbon  
25 atoms with the designation " $\Delta^{22}$ ". Thus, for example, the first named compound above could also be written as 2-ethyl-19-nor-22,23(E)- $\Delta^{22}$ -1,25-(OH)<sub>2</sub>D<sub>3</sub> where the double bond is in the (E) configuration. Similarly, if the methyl group attached at carbon 20 is in the unnatural configuration, this compound could be written as 2-ethyl-19-nor-20(S)-22,23(E)- $\Delta^{22}$ -1,25-(OH)<sub>2</sub>D<sub>3</sub>.

Specific and preferred examples of the 2-ethyl-compounds of structure II when the side chain is saturated are:

2-ethyl-19-nor-1,25-dihydroxyvitamin D<sub>3</sub>;

2-ethyl-19-nor-24-homo-1,25-dihydroxyvitamin D<sub>3</sub>;

5 2-ethyl-19-nor-24-dihomo-1,25-dihydroxyvitamin D<sub>3</sub>;

2-ethyl-19-nor-24-trihomo-1,25-dihydroxyvitamin D<sub>3</sub>;

2-ethyl-19-nor-26,27-dimethyl-24-homo-1,25-dihydroxyvitamin D<sub>3</sub>;

2-ethyl-19-nor-26,27-dimethyl-24-dihomo-1,25-dihydroxyvitamin D<sub>3</sub>;

2-ethyl-19-nor-26,27-dimethyl-24-trihomo-1,25-dihydroxyvitamin D<sub>3</sub>;

10 2-ethyl-19-nor-26,27-diethyl-24-homo-1,25-dihydroxyvitamin D<sub>3</sub>;

2-ethyl-19-nor-26,27-diethyl-24-dihomo-1,25-dihydroxyvitamin D<sub>3</sub>;

2-ethyl-19-nor-26,27-diethyl-24-trihomo-1,25-dihydroxyvitamin D<sub>3</sub>;

2-ethyl-19-nor-26,27-dipropyl-24-homo-1,25-dihydroxyvitamin D<sub>3</sub>;

2-ethyl-19-nor-26,27-dipropyl-24-dihomo-1,25-dihydroxyvitamin D<sub>3</sub>; and

15 2-ethyl-19-nor-26,27-dipropyl-24-trihomo-1,25-dihydroxyvitamin D<sub>3</sub>.

As noted previously, the above saturated side chain compounds should have the appropriate 2 $\alpha$ - or 2 $\beta$ - configuration and/or carbon 20 configuration added to the nomenclature. For example, particularly preferred compounds are:


19-nor-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>;

20 19-nor-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>;

19-nor-20(S)-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>; and

19-nor-20(S)-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

The preparation of 2-ethylidene-19-nor-vitamin D compounds, and the 2-ethyl-19-nor-vitamin D compounds, having the basic structure I and II can be accomplished by a  
 25 common general method, i.e. the condensation of a bicyclic Windaus-Grundmann type ketone III with the allylic phosphine oxide IVa or IVb to the corresponding 2-ethylidene-19-nor-vitamin D analogs Va or Vb, respectively followed by a selective reduction of the ethylidene group at C-2 to the corresponding 2-ethyl compounds.



In the structures III, IV, and V groups  $Y_1$  and  $Y_2$  and R represent groups defined above;  $Y_1$  and  $Y_2$  are preferably hydroxy-protecting groups, it being also understood that any



5 functionalities in R that might be sensitive, or that interfere with the condensation reaction, be suitable protected as is well-known in the art. The process shown above represents an application of the convergent synthesis concept, which has been applied effectively for the preparation of vitamin D compounds [e.g. Lythgoe et al., J. Chem. Soc. Perkin Trans. I, 590 (1978); Lythgoe, Chem. Soc. Rev. 9, 449 (1983); Toh et al., J. Org. Chem. 48, 1414



10 (1983); Baggiolini et al., J. Org. Chem. 51, 3098 (1986); Sardina et al., J. Org. Chem. 51,

1264 (1986); J. Org. Chem. 51, 1269 (1986); DeLuca et al., U.S. Pat. No. 5,086,191; DeLuca et al., U.S. Pat. No. 5,536,713].

Hydrindanones of the general structure III are known, or can be prepared by known methods. Specific important examples of such known bicyclic ketones are the structures with the side chains (a), (b), (c) and (d) described above, i.e. 25-hydroxy Grundmann's ketone (f) [Baggiolini et al., J. Org. Chem., 51, 3098 (1986)]; Grundmann's ketone (g) [Inhoffen et al., Chem. Ber. 90, 664 (1957)]; 25-hydroxy Windaus ketone (h) [Baggiolini et al., J. Org. Chem., 51, 3098 (1986)] and Windaus ketone (i) [Windaus et al., Ann., 524, 297 (1936)]:

10





For the preparation of the required phosphine oxides of general structure IV, a new synthetic route has been developed starting from methyl quinate derivative 9, easily obtained from commercial (1R,3R,4S,5R)-(-)-quinic acid 8 as described by Perlman et al., Tetrahedron Lett. 32, 7663 (1991) and DeLuca et al., U.S. Pat. No. 5,086,191. The overall process of transformation of the starting methyl ester 9 into the desired A-ring synthons, is summarized by the Scheme I. Reduction of the ester 9 with diisobutylaluminum hydride (DIBALH) or other suitable reducing agent (e.g. lithium aluminum hydride) provided the diol 10 which was subsequently oxidized by sodium periodate to the cyclohexanone ketone derivative 11. Then, the secondary 4-hydroxyl group of 11 was oxidized with  $RuO_4$  (a catalytic method with  $RuCl_3$  and  $NaIO_4$  as co-oxidant). Use of such a strong oxidant was necessary for an effective oxidation process of this very hindered hydroxyl.

However, other more commonly used oxidants can also be applied (e.g. pyridinium dichromate), although the reactions usually require much longer time for completion. The next step of the process comprises the Peterson reaction of the ketone 12 with methyl(trimethylsilyl)acetate to form ester 13.

5 Referring now to Scheme 2, the next step of the synthesis comprises the Wittig reaction of the sterically hindered 4-keto compound 13 with ylide prepared from ethyltriphenylphosphonium bromide and *n*-butyllithium leading to ethylidene compounds 14 and 15. Ethylidene compounds 14 and 15 in turn were treated with diisobutylaluminum hydride and the formed alcohols 16 and 17 were in turn transformed  
10 to the desired A-ring phosphine oxides 18 and 19. Conversion of 16 and 17, to 18 and 19, respectively involved 3 steps, namely, *in situ* tosylation with *n*-butyllithium and *p*-toluenesulfonyl chloride, followed by reaction with diphenylphosphine lithium salt and oxidation with hydrogen peroxide.

Several 2-ethylidene-19-nor-vitamin D compounds of the general structure V  
15 may be synthesized using the A-ring synthons 18 and 19 and the appropriate Windaus-Grundmann ketone III having the desired side chain structure. Thus, for example, Scheme 3 illustrates that Wittig-Horner coupling of the phosphinoxy 18 with the protected 25-hydroxy Grundmann's ketone 20 prepared according to published procedure [Sicinski et al., J. Med. Chem. 37, 3730 (1994)] gave the expected protected vitamin compound 21.  
20 This, after deprotection afforded 1 $\alpha$ ,25-dihydroxy-2(E)-ethylidene-19-nor-vitamin D<sub>3</sub> (4a). Similarly, Scheme 3 illustrates the synthesis of 1 $\alpha$ ,25-dihydroxy-2(Z)-ethylidene-19-nor-vitamin D<sub>3</sub> (5a) from phosphinoxy 19 and Grundmann's ketone 20.

Referring now to Scheme 6, the final step of the process was the selective homogeneous catalytic hydrogenation of the ethylidene unit at carbon 2 in the vitamins 4a  
25 and 5a performed efficiently in the presence of tris(triphenylphosphine)rhodium(I) chloride [Wilkinson's catalyst, (Ph<sub>3</sub>P)<sub>3</sub>RhCl]. Such reduction conditions allowed to reduce only C(2)=CH<sub>2</sub> unit leaving C(5)-C(8) butadiene moiety unaffected. The isolated material is an epimeric mixture (ca. 1:1) of 2-ethyl-19-nor-vitamins 6a and 7a differing in configuration at C-2. The mixture can be used without separation or, if desired, the  
30 individual 2 $\alpha$ - and 2 $\beta$ -isomers can be separated by an efficient HPLC system.

The C-20 epimerization may be accomplished by the analogous coupling of the phosphine oxides 18 and 19 with protected 20(*S*)-25-hydroxy Grundmann's ketone 26 (Scheme 5) which after hydrolysis of the hydroxy-protecting groups gave 20(*S*)-1 $\alpha$ ,25-dihydroxy-2-ethylidene-19-nor-vitamin D<sub>3</sub> compounds 4b and 5b. Hydrogenation of 4b and 5b provided the expected mixture of the 2-ethyl-19-nor-vitamin D analogs 6b and 7b.

As noted above, other 2-ethylidene and 2-ethyl-19-nor-vitamin D analogs may be synthesized by the method disclosed herein. For example, 1 $\alpha$ -hydroxy-2-ethylidene-19-nor-vitamin D<sub>3</sub> can be obtained by providing the Grundmann's ketone (g). Subsequent reduction of the A-ring ethylidene group in the formed compound can also give the corresponding epimeric mixture of 1 $\alpha$ -hydroxy-2-ethyl-19-nor-vitamin D<sub>3</sub> compounds.

A number of oxa-analogs of vitamin D<sub>3</sub> and their synthesis are also known. For example, 20-oxa analogs are described in N. Kubodera et al, Chem. Pharm. Bull., 34, 2286 (1986), and Abe et al, FEBS Lett. 222, 58, 1987. Several 22-oxa analogs are described in E. Murayama et al, Chem. Pharm. Bull., 34, 4410 (1986), Abe et al, FEBS Lett., 226, 58 (1987), PCT International Application No. WO 90/09991 and European Patent Application, publication number 184 112, and a 23-oxa analog is described in European Patent Application, publication number 78704, as well as U.S. Patent 4,772,433.

This invention is described by the following illustrative examples. In these examples specific products identified by Arabic numerals (e.g. 1, 2, 3, etc) refer to the specific structures so identified in the preceding description and in the Schemes.

#### EXAMPLE 1

#### CHEMISTRY

The strategy of the synthesis of 2-substituted 19-norvitamins was based on Lythgoe-type Wittig-Horner coupling. Since the corresponding C,D-ring ketones were available, attention was focused on the synthesis of the phosphine oxide A-ring synthons (Scheme 1 and 2). Configurations of the ethylidene unit at C'-4 in the isomeric compounds 16, 17 (Figure 2) and 17, 18, as well as their preferred conformations, were determined by analysis of <sup>1</sup>H NMR spectra, NOE measurements and spin decoupling experiments.

The Wittig-Horner reaction of the conjugate base of 20 with the protected 25-hydroxy Grundmann's ketone 20 produced 19-norvitamin D compound 21 in a very high yield, i.e. 91% (Scheme 3), but the yield of an analogous coupling of the isomeric phosphine oxide 19 was very low, i.e. 13%. The obtained condensation products 21 and 22, following deprotection, gave 2-ethylidene-19-norvitamins 4a and 5a. Considering the low yield of the Wittig reaction of the cyclohexanone 13, leading to ethylidene compounds 14 and 15 (Scheme 2), an alternative synthetic approach was sought.

Thus, the carbonyl group in 13 was protected as O-trimethylsilyl hemimethylthioketal and the corresponding phosphine oxides 25 were efficiently synthesized (Scheme 4). Coupling of their anions with the hydrindanone 26 (Scheme 5) afforded the protected 19-norvitamin D compound 27 in a high yield. This, after deprotection of 2-oxo group, Wittig reaction and subsequent hydrolysis was converted to (20S)-2-ethylidene-19-norvitamins 4b and 5b. The selective catalytic hydrogenation of 2-ethylidene analogs 4a, b and 5a, b (Scheme 6) provided the corresponding 2-ethyl-19-norvitamins 6a, b and 7a, b, which were easily separated by HPLC.

Stereochemistry at C-2 in the synthesized vitamin D compounds was tentatively assigned on the basis of conformational analysis, molecular modeling studies, and 500 MHz <sup>1</sup>H NMR spectroscopy.

## EXAMPLE 2

### CONFORMATIONAL ANALYSIS

It has been established that vitamin D compounds in solutions exist as a mixture of two rapidly equilibrating A-ring chair conformers abbreviated as  $\alpha$ - and  $\beta$ -forms (Figure 3a). Presence of bulky 2-alkyl substituents, characterized by large conformational free energy *A* values (Figure 3b), shifts the A-ring conformational equilibrium of the synthesized 2-ethyl-19-norvitamins toward the conformers with the equatorial C(2)-substituents. In the obtained 2-ethylidene-19-norvitamin D compounds, an additional strong interaction (designated as A<sup>(1,3)</sup>-strain, Figure 3c) is involved, existing between the methyl group from the ethylidene moiety and equatorial hydroxyls at C-1 or C-3. It



results in the strong bias toward conformers with an axial orientation of this hydroxy group to which the methyl from ethylidene fragment is directed.

Conformational equilibrium in ring A of 2-methylene-19-norvitamin 2 (a) and the preferred, energy minimized (PC MODEL 6.0, Serena Software) A-ring conformations of the synthesized analogs: 4a, b (b), 5a, b (c), 6a, b (d) and 7a, b (e) are shown in Figure 4. The steric energy differences between the preferred conformers and their partners with the inverted chair forms (calculated for model compounds lacking side chain) are given. The corresponding percentage populations (in parentheses) of conformers are given for room temperature (25°C).

### EXAMPLE 3

#### BIOLOGICAL EVALUATION

The synthesized vitamins were tested for their ability to bind the porcine intestinal vitamin D receptor. The presented results (Figure 5a) indicate that 2-ethylidene-19-norvitamins, possessing methyl group from ethylidene moiety directed toward C-3, i.e. *trans* in relation to C(6)-C(7) bond (isomers *E*), are more active than  $1\alpha,25-(\text{OH})_2\text{D}_3$  in binding to VDR, whereas their counterparts with *cis* relationship between ethylidene methyl substituent and C(7)-H group (isomers *Z*) exhibit significantly reduced affinity for the receptor. The competitive binding analysis showed also that  $2\alpha$ -ethyl-19-norvitamins bind the receptor better than their isomers with  $2\beta$ -ethyl substituents (Figure 5b). In the next assay, the cellular activity of the synthesized compounds was established by studying their ability to induce differentiation of human promyelocyte HL-60 cells into monocytes. *E* isomer of (20*S*)-2-ethylidene-19-norvitamin  $\text{D}_3$  (Figure 6a) and both  $2\alpha$ -ethyl-19-norvitamins (Figure 6b) are more potent than  $1\alpha,25-(\text{OH})_2\text{D}_3$  in this assay, whereas the remaining tested compounds are almost equivalent to the hormone.

Both *E* isomers of 2-ethylidene-19-norvitamins, when tested *in vivo* in rats (Table 1) exhibited very high calcemic activity, the (20*S*)-compound being especially potent. On the contrary, isomeric *Z* compounds are significantly less active. 2-ethyl-19-norvitamins have some ability to mobilize calcium from bone but not to the extent of the

hormone 1, while being inactive in intestine. The only exception is 2 $\alpha$ -ethyl isomer from 20*S*-series that shows strong calcium mobilization response and marked intestinal activity.

Table 1  
Support of Intestinal Calcium Transport and Bone Calcium Mobilization  
By 2-Substituted Analogs of 1 $\alpha$ ,25-Dihydroxy-19-norvitamin D<sub>3</sub>  
In Vitamin D-Deficient Rats on a Low-Calcium Diet<sup>a</sup>

compound	compd. no.	amount (pmol)	Ca transport S/M (mean $\pm$ SEM)	Serum Ca (mean $\pm$ SEM)
none (control)		0	3.0 $\pm$ 0.7	4.3 $\pm$ 0.1
1 $\alpha$ ,25-(OH) <sub>2</sub> D <sub>3</sub>	1	130	5.5 $\pm$ 0.5	5.1 $\pm$ 0.3
		260	5.9 $\pm$ 0.4	5.8 $\pm$ 0.3
2-ethylidene-19-nor- 1 $\alpha$ ,25-(OH) <sub>2</sub> D <sub>3</sub> ( <i>E</i> -isomer)	4a	65	5.0 $\pm$ 0.4	4.5 $\pm$ 0.1
		130	6.8 $\pm$ 0.4	5.2 $\pm$ 0.2
2-ethylidene-19-nor- 1 $\alpha$ ,25-(OH) <sub>2</sub> D <sub>3</sub> ( <i>Z</i> -isomer)	5a	65	4.4 $\pm$ 0.4	4.4 $\pm$ 0.2
		130	5.7 $\pm$ 0.9	4.2 $\pm$ 0.0
none (control)		0	4.4 $\pm$ 0.2	4.1 $\pm$ 0.2
1 $\alpha$ ,25-(OH) <sub>2</sub> D <sub>3</sub>	1	130	4.9 $\pm$ 0.7	5.2 $\pm$ 0.2
		260	6.0 $\pm$ 0.9	6.4 $\pm$ 0.4
2-ethylidene-19-nor-(20 <i>S</i> )- 1 $\alpha$ ,25-(OH) <sub>2</sub> D <sub>3</sub> ( <i>E</i> -isomer)	4b	65	9.0 $\pm$ 0.3	8.2 $\pm$ 0.3
		130	5.8 $\pm$ 0.8	12.1 $\pm$ 0.6
2-ethylidene-19-nor-(20 <i>S</i> )- 1 $\alpha$ ,25-(OH) <sub>2</sub> D <sub>3</sub> ( <i>Z</i> -isomer)	5b	65	4.3 $\pm$ 0.7	4.0 $\pm$ 0.3
		130	3.8 $\pm$ 0.3	4.0 $\pm$ 0.1

compound	compd. no.	amount (pmol)	Ca transport S/M (mean $\pm$ SEM)	Serum Ca (mean $\pm$ SEM)
none (control)		0	3.8 $\pm$ 0.4	3.9 $\pm$ 0.1
1 $\alpha$ ,25-(OH) <sub>2</sub> D <sub>3</sub>	1	260	6.5 $\pm$ 0.9	5.8 $\pm$ 0.1
2 $\alpha$ -ethyl-19-nor-1 $\alpha$ ,25-(OH) <sub>2</sub> D <sub>3</sub>	6a	260	4.0 $\pm$ 0.4	5.1 $\pm$ 0.1
2 $\beta$ -ethyl-19-nor-1 $\alpha$ ,25-(OH) <sub>2</sub> D <sub>3</sub>	7a	260	3.7 $\pm$ 0.3	5.0 $\pm$ 0.1
2 $\alpha$ -ethyl-19-nor-(20S)-1 $\alpha$ ,25-(OH) <sub>2</sub> D <sub>3</sub>	6b	260	5.0 $\pm$ 0.4	7.0 $\pm$ 0.1
2 $\beta$ -ethyl-19-nor-(20S)-1 $\alpha$ ,25-(OH) <sub>2</sub> D <sub>3</sub>	7b	260	4.1 $\pm$ 0.3	5.6 $\pm$ 0.1

<sup>a</sup>Weanling male rats were maintained on a 0.47% Ca diet for one week and then switched to a low-calcium diet containing 0.02% Ca for an additional three weeks. During the last week, they were dosed daily with the appropriate vitamin D compound for seven consecutive days. All doses were administered intraperitoneally in 0.1 mL propylene glycol/ethanol (95:5). Controls received the vehicle. Determinations were made 24 hours after the last dose. There were at least six rats per group.

For treatment purposes, the novel compounds of this invention defined by formula I and/or II may be formulated for pharmaceutical applications as a solution in innocuous solvents, or as an emulsion, suspension or dispersion in suitable solvents or carriers, or as pills, tablets or capsules, together with solid carriers, according to conventional methods known in the art. Any such formulations may also contain other pharmaceutically-acceptable and non-toxic excipients such as stabilizers, anti-oxidants, binders, coloring agents or emulsifying or taste-modifying agents.

The compounds may be administered orally, topically, parenterally, sublingually, intranasally, or transdermally. The compounds are advantageously administered by injection or by intravenous infusion or suitable sterile solutions, or in the form of liquid or

solid doses via the alimentary canal, or in the form of creams, ointments, patches, or similar vehicles suitable for transdermal applications. Doses of from about 0.01 $\mu$ g to about 100 $\mu$ g per day, preferably from 0.1 $\mu$ g to 50 $\mu$ g per day of the compounds are appropriate for treatment purposes, such doses being adjusted according to the disease to be treated, its severity and the response of the subject as is well understood in the art. Since the new compounds exhibit specificity of action, each may be suitably administered alone, or together with graded doses of another active vitamin D compound -- e.g. 1 $\alpha$ -hydroxyvitamin D<sub>2</sub> or D<sub>3</sub>, or 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> -- in situations where different degrees of bone mineral mobilization and calcium transport stimulation is found to be advantageous.

Compositions for use in the above-mentioned treatment of psoriasis and other malignancies comprise an effective amount of one or more 2-substituted-19-nor-vitamin D compound as defined by the above formula I and/or II as the active ingredient, and a suitable carrier. An effective amount of such compounds for use in accordance with this invention is from about 0.01 $\mu$ g to about 100 $\mu$ g per gm of composition, and may be administered topically, transdermally, orally, sublingually, intranasally, or parenterally in dosages of from about 0.1 $\mu$ g/day to about 100 $\mu$ g/day.

The compounds may be formulated as creams, lotions, ointments, topical patches, pills, capsules or tablets, or in liquid form as solutions, emulsions, dispersions, or suspensions in pharmaceutically innocuous and acceptable solvent or oils, and such preparations may contain in addition other pharmaceutically innocuous or beneficial components, such as stabilizers, antioxidants, emulsifiers, coloring agents, binders or taste-modifying agents.

The compounds are advantageously administered in amounts sufficient to effect the differentiation of promyelocytes to normal macrophages. Dosages as described above are suitable, it being understood that the amounts given are to be adjusted in accordance with the severity of the disease, and the condition and response of the subject as is well understood in the art.

The formulations of the present invention comprise an active ingredient in association with a pharmaceutically acceptable carrier therefore and optionally other

therapeutic ingredients. The carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulations and not deleterious to the recipient thereof.

Formulations of the present invention suitable for oral administration may be in the form of discrete units as capsules, sachets, tablets or lozenges, each containing a predetermined amount of the active ingredient; in the form of a powder or granules; in the form of a solution or a suspension in an aqueous liquid or non-aqueous liquid; or in the form of an oil-in-water emulsion or a water-in-oil emulsion.

Formulations for rectal administration may be in the form of a suppository incorporating the active ingredient and carrier such as cocoa butter, or in the form of an enema.

Formulations suitable for parenteral administration conveniently comprise a sterile oily or aqueous preparation of the active ingredient which is preferably isotonic with the blood of the recipient.

Formulations suitable for topical administration include liquid or semi-liquid preparations such as liniments, lotions, applicants, oil-in-water or water-in-oil emulsions such as creams, ointments or pastes; or solutions or suspensions such as drops; or as sprays.


For asthma treatment, inhalation of powder, self-propelling or spray formulations, dispensed with a spray can, a nebulizer or an atomizer can be used. The formulations, when dispensed, preferably have a particle size in the range of 10 to 100 $\mu$ .

The formulations may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. By the term "dosage unit" is meant a unitary, i.e. a single dose which is capable of being administered to a patient as a physically and chemically stable unit dose comprising either the active ingredient as such or a mixture of it with solid or liquid pharmaceutical diluents or carriers.


In its broadest application, the present invention relates to any 19-nor-analog of vitamin D which have the vitamin D nucleus. By vitamin D nucleus, it is meant a central part consisting of a substituted chain of five carbon atoms which correspond to positions 8, 14, 13, 17 and 20 of vitamin D, and at the ends of which are connected at position 20 a

structural moiety representing any of the typical side chains known for vitamin D type compounds (such as R as previously defined herein), and at position 8 the 5,7-diene moiety connected to the A-ring of an active  $1\alpha$ -hydroxy vitamin D analog (as illustrated by formula I herein). Thus, various known modifications to the six-membered C-ring and  
5 the five-membered D-ring typically present in vitamin D, such as the lack of one or the other or both, are also embraced by the present invention.

## Scheme 1





## Scheme 2







## Scheme 3



## Scheme 4




$^1\text{H}$ - $^1\text{H}$  coupling constants  
 $J_{5\beta,6\alpha} = \text{ca. } 11 \text{ Hz}$   
 $J_{5\beta,6\beta} = \text{ca. } 4.5 \text{ Hz}$


$\text{R} = \text{Si}(\text{tBu})_2\text{OMe}$   
 $\text{X} = \text{COOMe},$   
 $\text{CH}_2\text{OH},$   
 $\text{CH}_2\text{POPh}_2$

$^1\text{H}$ - $^1\text{H}$  coupling constants  
 $J_{2\alpha,3\alpha} = \text{ca. } 4.5 \text{ Hz}$   
 $J_{2\beta,3\alpha} = \text{ca. } 11 \text{ Hz}$



Configurations and preferred conformations of 4'-methylthio-4'-trimethylsilyloxy compounds were determined by  $^1\text{H}$  NMR spectra and  $^1\text{H}$  NOE experiments



Scheme 5



Scheme 6



## CLAIMS

1. 19-nor-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.
2. 19-nor-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.
3. 19-nor-20(S)-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.
4. 19-nor-20(S)-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.
5. 19-nor-2(E)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.
6. 19-nor-2(Z)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.
7. 19-nor-2(E)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.
8. 19-nor-2(Z)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.
9. A pharmaceutical composition containing 19-nor-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> together with a pharmaceutically acceptable excipient.
10. The pharmaceutical composition of claim 9 containing 19-nor-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> in an amount of from about 0.01 $\mu$ g to about 100 $\mu$ g per gram of the composition.
11. The pharmaceutical composition of claim 9 containing 19-nor-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> in an amount from about 0.1 $\mu$ g to about 50 $\mu$ g per gram of the composition.
12. The pharmaceutical composition of claim 9 suitable for oral administration.
13. The pharmaceutical composition of claim 9 suitable for topical administration.
14. The pharmaceutical composition of claim 9 suitable for parenteral administration.
15. A pharmaceutical composition containing 19-nor-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> together with a pharmaceutically acceptable excipient.
16. The pharmaceutical composition of claim 15 containing 19-nor-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> in an amount from about 0.01 $\mu$ g to about 100 $\mu$ g per gram of the composition.

17. The pharmaceutical composition of claim 15 containing 19-nor-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> in an amount from about 0.1 $\mu$ g to about 50 $\mu$ g per gram of the composition.
18. The pharmaceutical composition of claim 15 suitable for oral administration.
19. The pharmaceutical composition of claim 15 suitable for topical administration.
20. The pharmaceutical composition of claim 15 suitable for parenteral administration.
21. A pharmaceutical composition containing 19-nor-20(S)-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> together with a pharmaceutically acceptable excipient.
22. The pharmaceutical composition of claim 21 containing 19-nor-20(S)-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> in an amount from about 0.01 $\mu$ g to about 100 $\mu$ g per gram of the composition.
23. The pharmaceutical composition of claim 21 containing 19-nor-20(S)-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> in an amount from about 0.1 $\mu$ g to about 50 $\mu$ g per gram of the composition.
24. The pharmaceutical composition of claim 21 suitable for oral administration.
25. The pharmaceutical composition of claim 21 suitable for topical administration.
26. The pharmaceutical composition of claim 21 suitable for parenteral administration.
27. A pharmaceutical composition containing 19-nor-20(S)-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> together with a pharmaceutically acceptable excipient.
28. The pharmaceutical composition of claim 27 containing 19-nor-20(S)-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> in an amount from about 0.01 $\mu$ g to about 100 $\mu$ g per gram of the composition.
29. The pharmaceutical composition of claim 27 containing 19-nor-20(S)-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> in an amount from about 0.1 $\mu$ g to about 50 $\mu$ g per gram of the composition.

30. The pharmaceutical composition of claim 27 suitable for oral administration.

31. The pharmaceutical composition of claim 27 suitable for topical administration.

32. The pharmaceutical composition of claim 27 suitable for parenteral administration.

33. A pharmaceutical composition containing 19-nor-2(E)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> together with a pharmaceutically acceptable excipient.

34. The pharmaceutical composition of claim 33 containing 19-nor-2(E)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> in an amount from about 0.01 $\mu$ g to about 100 $\mu$ g per gram of the composition.

35. The pharmaceutical composition of claim 33 containing 19-nor-2(E)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> in an amount from about 0.1 $\mu$ g to about 50 $\mu$ g per gram of the composition.

36. The pharmaceutical composition of claim 33 suitable for oral administration.

37. The pharmaceutical composition of claim 33 suitable for topical administration.

38. The pharmaceutical composition of claim 33 suitable for parenteral administration.

39. A pharmaceutical composition containing 19-nor-2(Z)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> together with a pharmaceutically acceptable excipient.

40. The pharmaceutical composition of claim 39 containing 19-nor-2(Z)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> in an amount from about 0.01 $\mu$ g to about 100 $\mu$ g per gram of the composition.

41. The pharmaceutical composition of claim 39 containing 19-nor-2(Z)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> in an amount from about 0.1 $\mu$ g to about 50 $\mu$ g per gram of the composition.

42. The pharmaceutical composition of claim 39 suitable for oral administration.

43. The pharmaceutical composition of claim 39 suitable for topical administration.

44. The pharmaceutical composition of claim 39 suitable for parenteral administration.
45. A pharmaceutical composition containing 19-nor-2(E)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> together with a pharmaceutically acceptable excipient.
46. The pharmaceutical composition of claim 45 containing 19-nor-2(E)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> in an amount from about 0.01 $\mu$ g to about 100 $\mu$ g per gram of the composition.
47. The pharmaceutical composition of claim 45 containing 19-nor-2(E)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> in an amount from about 0.1 $\mu$ g to about 50 $\mu$ g per gram of the composition.
48. The pharmaceutical composition of claim 45 suitable for oral administration.
49. The pharmaceutical composition of claim 45 suitable for topical administration.
50. The pharmaceutical composition of claim 45 suitable for parenteral administration.
51. A pharmaceutical composition containing 19-nor-2(Z)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> together with a pharmaceutically acceptable excipient.
52. The pharmaceutical composition of claim 51 containing 19-nor-2(Z)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> in an amount from about 0.01 $\mu$ g to about 100 $\mu$ g per gram of the composition.
53. The pharmaceutical composition of claim 51 containing 19-nor-2(Z)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> in an amount from about 0.1 $\mu$ g to about 50 $\mu$ g per gram of the composition.
54. The pharmaceutical composition of claim 51 suitable for oral administration.
55. The pharmaceutical composition of claim 51 suitable for topical administration.
56. The pharmaceutical composition of claim 51 suitable for parenteral administration.



57. A method of treating a metabolic bone disease where it is desired to maintain or increase bone mass comprising administering to a patient with said disease an effective amount of a compound selected from the group consisting of

- 5           19-nor-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,  
          19-nor-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,  
          19-nor-20(S)-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,  
          19-nor-20(S)-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,  
          19-nor-2(E)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,  
          19-nor-2(Z)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,  
10          19-nor-2(E)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,  
          19-nor-2(Z)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.
58. The method of claim 57 where the disease is senile osteoporosis.
59. The method of claim 57 where the disease is postmenopausal osteoporosis.
60. The method of claim 57 where the disease is steroid-induced osteoporosis.
61. The method of claim 57 where the disease is low bone turnover  
osteoporosis.
62. The method of claim 57 where the disease is osteomalacia.
63. The method of claim 57 where the disease is renal osteodystrophy.
64. The method of claim 57 wherein the compound is administered orally.
65. The method of claim 57 wherein the compound is administered  
parenterally.
66. The method of claim 57 wherein the compound is administered  
transdermally.
67. The method of claim 57 wherein the compound is administered in a dosage  
of from about 0.01  $\mu$ g to about 50  $\mu$ g per day.
68. The method of claim 57 wherein the compound is 19-nor-2 $\alpha$ -ethyl-1 $\alpha$ ,25-  
dihydroxyvitamin D<sub>3</sub>.
69. The method of claim 57 wherein the compound is 19-nor-2 $\beta$ -ethyl-1 $\alpha$ ,25-  
dihydroxyvitamin D<sub>3</sub>.
70. The method of claim 57 wherein the compound is 19-nor-20(S)-2 $\alpha$ -ethyl-  
1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

71. The method of claim 57 wherein the compound is 19-nor-20(S)-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

72. The method of claim 57 wherein the compound is 19-nor-2(E)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

73. The method of claim 57 wherein the compound is 19-nor-2(Z)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

74. The method of claim 57 wherein the compound is 19-nor-2(E)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

75. The method of claim 57 wherein the compound is 19-nor-2(Z)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

76. A method of treating psoriasis comprising administering to a patient with psoriasis an effective amount of a compound selected from the group consisting of

19-nor-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,

19-nor-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,

19-nor-20(S)-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,

19-nor-20(S)-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,

19-nor-2(E)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,

19-nor-2(Z)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,

19-nor-2(E)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>, and

19-nor-2(Z)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

77. The method of claim 76 wherein said effective amount comprises about 0.1 $\mu$ g/day to about 100 $\mu$ g/day of said compound.

78. The method of claim 76 wherein the compound is 19-nor-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

79. The method of claim 76 wherein the compound is 19-nor-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

80. The method of claim 76 wherein the compound is 19-nor-20(S)-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

81. The method of claim 76 wherein the compound is 19-nor-20(S)-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

82. The method of claim 76 wherein the compound is 19-nor-2(E)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

83. The method of claim 76 wherein the compound is 19-nor-2(Z)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

84. The method of claim 76 wherein the compound is 19-nor-2(E)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

85. The method of claim 76 wherein the compound is 19-nor-2(Z)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

86. A method of treating a cancerous disease comprising administering to a patient with said disease an effective amount of a compound selected from the group consisting of

- 5                   19-nor-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,  
                  19-nor-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,  
                  19-nor-20(S)-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,  
                  19-nor-20(S)-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,  
                  19-nor-2(E)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,  
                  19-nor-2(Z)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,  
10               19-nor-2(E)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>, and  
                  19-nor-2(Z)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

87. The method of claim 86 where the disease is leukemia.

88. The method of claim 86 where the disease is colon cancer.

89. The method of claim 86 where the disease is breast cancer.

90. The method of claim 86 where the disease is prostate cancer.

91. The method of claim 86 wherein the compound is administered orally.

92. The method of claim 86 wherein the compound is administered parenterally.

93. The method of claim 86 wherein the compound is administered transdermally.

94. The method of claim 86 wherein the compound is administered in a dosage of from about 0.01 $\mu$ g to about 100 $\mu$ g per day.

95. The method of claim 86 wherein the compound is 19-nor-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

96. The method of claim 86 wherein the compound is 19-nor-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

97. The method of claim 86 wherein the compound is 19-nor-20(S)-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

98. The method of claim 86 wherein the compound is 19-nor-20(S)-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

99. The method of claim 86 wherein the compound is 19-nor-2(E)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

100. The method of claim 86 wherein the compound is 19-nor-2(Z)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

101. The method of claim 86 wherein the compound is 19-nor-2(E)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

102. The method of claim 86 wherein the compound is 19-nor-2(Z)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

103. A method of treating a disease characterized by an imbalance in the immune system comprising administering to a patient with said disease an effective amount of a compound selected from the group consisting of

19-nor-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,

19-nor-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,

19-nor-20(S)-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,

19-nor-20(S)-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,

19-nor-2(E)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,

19-nor-2(Z)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,

19-nor-2(E)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>, and

19-nor-2(Z)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

104. The method of claim 103 where the disease is multiple sclerosis.

105. The method of claim 103 where the disease is diabetes mellitus.

106. The method of claim 103 where the disease is transplant rejection.

107. The method of claim 103 where the disease is lupus.

108. The method of claim 103 where the disease is atherosclerosis.

109. A method of treating rheumatoid arthritis comprising administering to a patient with rheumatoid arthritis an effective amount of a compound selected from the group consisting of

- 19-nor-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,
- 5 19-nor-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,
- 19-nor-20(S)-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,
- 19-nor-20(S)-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,
- 19-nor-2(E)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,
- 19-nor-2(Z)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,
- 10 19-nor-2(E)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>, and
- 19-nor-2(Z)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

110. A method of treating alopecia comprising administering to a patient with alopecia an effective amount of a compound selected from the group consisting of

- 19-nor-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,
- 19-nor-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,
- 5 19-nor-20(S)-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,
- 19-nor-20(S)-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,
- 19-nor-2(E)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,
- 19-nor-2(Z)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,
- 19-nor-2(E)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>, and
- 10 19-nor-2(Z)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

111. The method of claim 110 wherein said alopecia is chemically induced alopecia.

112. A method of treating skin conditions selected from the group consisting of dermatitis, eczema, keratosis, lack of skin firmness, wrinkles, lack of dermal hydration and insufficient sebum secretion which comprises administering to a patient by topical, oral or parenteral means an effective amount of a compound selected from the group consisting of

- 5 19-nor-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,
- 19-nor-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,
- 19-nor-20(S)-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,
- 19-nor-20(S)-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,

- 10 19-nor-2(E)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,  
19-nor-2(Z)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,  
19-nor-2(E)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>, and  
19-nor-2(Z)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

113. A method of treating hypertension comprising administering to a patient with hypertension an effective amount of a compound selected from the group consisting of

- 5 19-nor-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,  
19-nor-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,  
19-nor-20(S)-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,  
19-nor-20(S)-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,  
19-nor-2(E)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,  
19-nor-2(Z)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,  
10 19-nor-2(E)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>, and  
19-nor-2(Z)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

114. A method of treating hypocalcemia comprising administering to a patient with hypocalcemia an effective amount of a compound selected from the group consisting of

- 5 19-nor-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,  
19-nor-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,  
19-nor-20(S)-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,  
19-nor-20(S)-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,  
19-nor-2(E)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,  
19-nor-2(Z)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,  
10 19-nor-2(E)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>, and  
19-nor-2(Z)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.


115. A method of treating hypoparathyroidism comprising administering to a patient with hypoparathyroidism an effective amount of a compound selected from the group consisting of

- 19-nor-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,
- 5 19-nor-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,
- 19-nor-20(S)-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,
- 19-nor-20(S)-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,
- 19-nor-2(E)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,
- 19-nor-2(Z)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,
- 10 19-nor-2(E)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>, and
- 19-nor-2(Z)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

116. A method of treating inflammatory bowel disease comprising administering to a patient with inflammatory bowel disease an effective amount of a compound selected from the group consisting of


- 19-nor-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,
- 5 19-nor-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,
- 19-nor-20(S)-2 $\alpha$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,
- 19-nor-20(S)-2 $\beta$ -ethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,
- 19-nor-2(E)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,
- 19-nor-2(Z)-ethylidene-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>,
- 10 19-nor-2(E)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>, and
- 19-nor-2(Z)-ethylidene-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

1/10




1 $\alpha$ ,25-dihydroxy-2 $\alpha$ -methyl-  
19-norvitamin D<sub>3</sub>

FIG. 1C



1 $\alpha$ ,25-dihydroxy-2-methylene-  
19-norvitamin D<sub>3</sub>

FIG. 1B



1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>

FIG. 1A



2/10




FIG. 1D

3/10

FIG. 2A





FIG. 2B



4 / 10

FIG. 3A





FIG. 3B



5 / 10

FIG. 3C





FIG. 4A

6/10

FIG. 4C




FIG. 4B




FIG. 4E





FIG. 4D



7/10




FIG. 5A

8/10




FIG. 5B

9/10




FIG. 6A



10/10




FIG. 6B

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/17662

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C401/00 A61K31/59

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 41500 A (WISCONSIN ALUMNI RESEARCH FOUNDATION) 24 September 1998 (1998-09-24)  page 3, line 5 - page 7, line 11; examples	1-32, 57-71, 76-81, 86-98, 103-110, 112-114
A	US 5 877 168 A (K. MIYAMOTO ET AL) 2 March 1999 (1999-03-02)  column 1, lines 10-18; column 2, lines 14-64; example 8;	1-4, 9, 15, 21, 27, 57, 62, 68-71, 86, 95-98

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*&\* document member of the same patent family

Date of the actual completion of the international search

12 September 2001

Date of mailing of the international search report

20/09/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Van Amsterdam, L

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/17662

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9841500 A	24-09-1998	US 5945410 A	31-08-1999
		AU 714390 B	23-12-1999
		AU 6280098 A	12-10-1998
		BR 9808010 A	08-03-2000
		EP 0971888 A	19-01-2000
		JP 2000513010 T	03-10-2000
		NO 994489 A	16-09-1999
		US 6127559 A	03-10-2000
		US 6277837 B	21-08-2001
US 5877168 A	02-03-1999	US 6124276 A	26-09-2000

**THIS PAGE BLANK (USPTO)**